MCA logo
MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

HSA Approves First-In-Class Sacituzumab Govitecan (Trodelvy) for Metastatic Triple Negative Breast Cancer (mTNBC)

breast cancer trodelvy sacituzumab govitecan

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: